Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Aligos Therapeutics $150 million IPO

Davis Polk advised  the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…

Eargo $165.2 million IPO

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9,029,629 shares of common stock of Eargo, Inc. at $18.00 per share …

H.B. Fuller $300 million notes offering

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered debt issuance by H.B. Fuller Company of $300 million of its 4.250% notes due 2028…

Royalty Pharma $728 million secondary offering

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Turmeric Acquisition $97.75 million IPO

Davis Polk advised the joint book-running managers in connection with the $97.75 million initial public offering of 9,775,000 units of Turmeric Acquisition Corp., which includes 1,275…

Array Technologies $1.2 billion IPO

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $1.2 billion initial public offering of 54,625,000 shares of common…
Back to top